MX2009009379A - Metodos y composiciones para tratar enfermedades tumorales. - Google Patents

Metodos y composiciones para tratar enfermedades tumorales.

Info

Publication number
MX2009009379A
MX2009009379A MX2009009379A MX2009009379A MX2009009379A MX 2009009379 A MX2009009379 A MX 2009009379A MX 2009009379 A MX2009009379 A MX 2009009379A MX 2009009379 A MX2009009379 A MX 2009009379A MX 2009009379 A MX2009009379 A MX 2009009379A
Authority
MX
Mexico
Prior art keywords
methods
igf
antibodies
derivatives
polypeptides
Prior art date
Application number
MX2009009379A
Other languages
English (en)
Inventor
Frank J Calzone
Pedro J Beltran
Gregory Friberg
Christopher Haqq
Anthony W Tolcher
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2009009379A publication Critical patent/MX2009009379A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

La presente invención proporciona, en parte, métodos para tratar un tumor en un sujeto humano que comprende inhibir la señalización del receptor IGF-l, métodos para determinar si un tumor es más o menos susceptible a responder al tratamiento y composiciones para llevar a la práctica los métodos. En modalidades particulares, la invención proporciona anticuerpos anti-IGF-1R completamente humanos, humanizados o quiméricos que se unen a fragmentos que se unen a IGF-1R humano, fragmentos que se unen a IGF-1R humano y derivados de los anticuerpos, y polipéptidos que se unen a IGF-1R que comprenden los fragmentos. Otras modalidades proporcionan ácidos nucleicos que codifican para los anticuerpos, fragmentos de anticuerpo y derivados y polipéptidos, células que comprenden los polinucleótidos, métodos de elaboración de los anticuerpos, fragmentos de anticuerpo y derivados y polipéptidos y métodos de uso de los anticuerpos, fragmentos de anticuerpo y derivados y polipéptidos, que incluyen métodos de tratamiento o diagnóstico de sujetos que tienen trastornos o condiciones relacionadas con IGF-1R.
MX2009009379A 2007-03-02 2008-02-29 Metodos y composiciones para tratar enfermedades tumorales. MX2009009379A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90453807P 2007-03-02 2007-03-02
PCT/US2008/002710 WO2008108986A2 (en) 2007-03-02 2008-02-29 Methods and compositions for treating tumor diseases

Publications (1)

Publication Number Publication Date
MX2009009379A true MX2009009379A (es) 2009-09-14

Family

ID=39683874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009379A MX2009009379A (es) 2007-03-02 2008-02-29 Metodos y composiciones para tratar enfermedades tumorales.

Country Status (8)

Country Link
US (2) US20100166747A1 (es)
EP (1) EP2129397B1 (es)
JP (1) JP2010520204A (es)
AU (1) AU2008223541B2 (es)
CA (1) CA2679548C (es)
ES (1) ES2707551T3 (es)
MX (1) MX2009009379A (es)
WO (1) WO2008108986A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
MX2008014608A (es) 2006-05-18 2009-03-31 Molecular Profiling Inst Inc Sistema y metodo para determinar la intervencion medica individualizada para un estado de enfermedad.
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
EP2727936B1 (en) 2006-11-22 2016-09-07 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
KR20100128291A (ko) 2008-02-14 2010-12-07 브리스톨-마이어스 스큅 컴퍼니 Ｅｇｆｒ에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제
WO2009142773A2 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
WO2009148623A2 (en) 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
EP2318552B1 (en) 2008-09-05 2016-11-23 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
CN107254538A (zh) 2008-11-12 2017-10-17 卡里斯生命科学瑞士控股有限责任公司 使用外来体来确定表现型的方法和***
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
TWI471139B (zh) 2008-12-12 2015-02-01 Boehringer Ingelheim Int 抗－ｉｇｆ抗體
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109572A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
WO2011163512A2 (en) * 2010-06-23 2011-12-29 Brandeis University Cancer therapy
EP2619329B1 (en) 2010-09-24 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
KR20140138353A (ko) 2011-04-19 2014-12-03 메리맥 파마슈티컬즈, 인크. 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
EP2540828A1 (en) * 2011-06-30 2013-01-02 Gene Signal International SA Composition comprising inhibitors of IRS-1 and of VEGF
AU2012277722B2 (en) 2011-06-30 2017-03-16 Gene Signal International Sa Composition comprising inhibitors of IRS-1 and of VEGF
US9682144B2 (en) 2011-06-30 2017-06-20 Gene Signal International, Sa Composition comprising inhibitors of IRS-1 and of VEGF
JP6268097B2 (ja) 2011-11-11 2018-01-24 デューク・ユニヴァーシティ 固形腫瘍治療のための併用薬物療法
US20140341922A1 (en) * 2011-11-25 2014-11-20 SUN R & D Foundation Method for Overcoming Tolerance to Targeted Anti-Cancer Agent
JP2015505843A (ja) * 2011-12-15 2015-02-26 ザ・ロイヤル・インスティテューション・フォア・ザ・アドバンスメント・オブ・ラーニング／マクギル・ユニヴァーシティ 可溶性ＩＧＦレセプターＦｃ融合タンパク質およびその使用
CN104487089B (zh) * 2012-03-20 2018-08-28 诺华股份有限公司 Mek抑制剂和igfir抑制剂的组合疗法
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
KR20220162886A (ko) 2014-03-20 2022-12-08 브리스톨-마이어스 스큅 컴퍼니 혈청 알부민-결합 피브로넥틴 유형 iii 도메인
JP6371463B2 (ja) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 即時放出性乱用抑止性液体充填剤形
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN106338423B (zh) 2015-07-10 2020-07-14 三斯坎公司 组织学染色的空间复用
KR20180056701A (ko) 2015-09-23 2018-05-29 브리스톨-마이어스 스큅 컴퍼니 패스트-오프 레이트 혈청 알부민 결합 피브로넥틴 유형 iii 도메인
CN112236131A (zh) 2018-03-29 2021-01-15 技术研究及发展基金有限公司 包含pten抑制剂的囊泡及其用途
CN113512116B (zh) 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
CA3230155A1 (en) * 2021-08-25 2023-03-02 Molecular Technologies Laboratories Llc Growth hormone antagonist and anti-cancer composition combination therapy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
JP2000500654A (ja) * 1995-11-14 2000-01-25 トーマス・ジェファーソン・ユニバーシティ 可溶性ｉｇｆ−１受容体による腫瘍成長に対する誘導耐性
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
ATE328903T1 (de) * 1997-11-27 2006-06-15 Commw Scient Ind Res Org Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462)
US6258845B1 (en) * 1998-03-28 2001-07-10 The Regents Of The University Of California DFMO and sulindac combination in cancer chemoprevention
EP1006184A1 (en) * 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
DK1141014T3 (da) * 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
NZ569856A (en) * 2001-01-05 2010-03-26 Pfizer Antibodies to insulin-like growth factor 1 receptor
CA2702192A1 (en) * 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
CA2450793A1 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EP1506286B1 (en) * 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Neutralizing human anti-igfr antibody
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
JP2007528201A (ja) * 2003-03-14 2007-10-11 ファルマシア・コーポレーション 癌治療のためのｉｇｆ−ｉ受容体に対する抗体
ATE549359T1 (de) * 2003-04-02 2012-03-15 Hoffmann La Roche Antikörper gegen den insulinähnlichen wachstumsfaktor i-rezeptor und deren verwendungen
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
UA85058C2 (ru) * 2003-08-13 2008-12-25 Пфайзер Продактс Инк. Модифицированное моноклональное антитело человека, которое специфически связывается с рецептором подобного к инсулину фактора роста i человека (igf-ir)
US20050059021A1 (en) * 2003-09-15 2005-03-17 Performance Genomics, Inc. Insulin-like growth factor-1 receptor (IGF-1R) polymorphic alleles and use of the same to identify DNA markers for reproductive longevity
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
CA2564538A1 (en) * 2004-04-22 2005-12-01 Oregon Health And Science University Compositions and methods for modulating signaling mediated by igf-1 receptor and erbb receptors
CN101014365B (zh) * 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP2460886B1 (en) * 2005-05-04 2014-01-01 University of South Florida Predicting treatment response in cancer subjects
JP2008540566A (ja) * 2005-05-12 2008-11-20 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド ２−デオキシグルコースを用いたがんの処置
CN102123712B (zh) * 2006-12-13 2014-03-19 默沙东公司 使用igf1r抑制剂治疗癌症的方法
AU2012212075A1 (en) * 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R

Also Published As

Publication number Publication date
EP2129397B1 (en) 2018-10-31
US11078288B2 (en) 2021-08-03
EP2129397A2 (en) 2009-12-09
ES2707551T3 (es) 2019-04-04
US20100166747A1 (en) 2010-07-01
AU2008223541B2 (en) 2012-04-05
JP2010520204A (ja) 2010-06-10
WO2008108986A2 (en) 2008-09-12
WO2008108986A3 (en) 2009-02-05
CA2679548A1 (en) 2008-09-12
US20190040141A1 (en) 2019-02-07
AU2008223541A1 (en) 2008-09-12
CA2679548C (en) 2015-01-27

Similar Documents

Publication Publication Date Title
MX2009009379A (es) Metodos y composiciones para tratar enfermedades tumorales.
MX2013008833A (es) Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
MX2007006921A (es) Composiciones que comprenden anticuerpos del receptor anti-factor de crecimiento tipo insulina 1 y metodos para obtener los anticuerpos.
MX2009002571A (es) Anticuerpos anti-activina a y usos de los mismos.
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
MX353319B (es) Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.
WO2007145840A3 (en) Compositions and methods for diagnosing and treating cancer
WO2007092640A3 (en) Antibodies that bind par-2
MX2012004084A (es) Anticuerpos siglec-15 para tratar enfermedad relacionada con perdida osea.
WO2013192596A3 (en) Antigen binding proteins that bind ccr2
WO2012170438A3 (en) HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING β-KLOTHO AND AN FGF RECEPTOR
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
MY191950A (en) Human antigen binding proteins that bind ?-klotho, fgf receptors and complexes thereof
WO2013181634A3 (en) Antigen binding proteins that bind pd-l1
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
SG170032A1 (en) Antagonistic human light-specific human monoclonal antibodies
EP3670534A3 (en) Human fgf receptor and beta-klotho binding proteins
BRPI0513890A (pt) anticorpo, hibridoma murino, composição, uso dos mesmos, e, método de diagnóstico in vitro de doenças
WO2008054561A3 (en) Proteins, nucleic acids encoding the same and associated methods of use
WO2009120905A3 (en) Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
WO2008105797A3 (en) Polynucleotides encoding novel pcsk9 variants
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
GEP20135826B (en) Novel antibodies used to treat cancer
US20180171027A1 (en) Biomarkers Related to Treatment of Cancer with HER3 and EGFR Inhibitors
WO2009148896A3 (en) Anti-phospho-akt antibodies

Legal Events

Date Code Title Description
FG Grant or registration